Clinical burden and management of HMB in women with VWD
| I. Clinical burden of HMB |
| Delay in diagnosis, difficulty accessing treatment21 |
| VWF levels masked by hormones, pregnancy, comorbidities7,8 |
| VWF assay high variability9,10 |
| Iron-deficiency anemia15 |
| Poor cognitive, social functioning, quality-of-life21-23 |
| Malposition, expulsion of intrauterine device26 |
| II. Current approach to management |
| Iron supplementation17-19 |
| Tranexamic acid24 |
| Levonorgestrel intrauterine device26 |
| Combined oral contraceptive24 |
| VWF concentrate24 |
| I. Clinical burden of HMB |
| Delay in diagnosis, difficulty accessing treatment21 |
| VWF levels masked by hormones, pregnancy, comorbidities7,8 |
| VWF assay high variability9,10 |
| Iron-deficiency anemia15 |
| Poor cognitive, social functioning, quality-of-life21-23 |
| Malposition, expulsion of intrauterine device26 |
| II. Current approach to management |
| Iron supplementation17-19 |
| Tranexamic acid24 |
| Levonorgestrel intrauterine device26 |
| Combined oral contraceptive24 |
| VWF concentrate24 |